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Introduction {#sec1}
============

Tuberculosis remains a major global threat that claimed 1.3 million lives in 2016 ([@bib50]). Moreover, one-third of the entire world population is estimated to be latently infected with *Mycobacterium tuberculosis*. Multiple factors contribute to the difficulty of eradicating tuberculosis; however, the remarkable ability of *M. tuberculosis* to persist *in vivo* and to survive stressful conditions is believed to be a major contributor to the success of this pathogen ([@bib48]). The ability of mycobacteria to adapt to varying environmental constraints is governed by numerous transcriptional, translational, and post-translational regulatory mechanisms. In particular, protein phosphorylation controls enzyme activity, protein-protein interactions, and protein localization. *M. tuberculosis* possesses 11 serine/threonine protein kinases ([@bib35]), two of which---protein kinase A (PknA) ([@bib30]) and protein kinase B (PknB) ([@bib14])---are essential for growth. PknB is one of the most studied mycobacterial proteins and is a verified drug target ([@bib42]). PknB has several domains, all of which are essential for its function ([@bib10], [@bib34]). The extracellular PASTA (penicillin-binding protein and serine/threonine kinase associated) domain is believed to recognize peptidoglycan fragments, and it has been implicated in PknB localization ([@bib52], [@bib26]), while the juxtamembrane domain recruits FhaA ([@bib38]) and possibly other proteins that control peptidoglycan biosynthesis. PknB has been shown to phosphorylate multiple substrates, including proteins involved in peptidoglycan biosynthesis and remodeling: PonA1 ([@bib22]), GlmU ([@bib31]), MviN ([@bib16]), and CwlM ([@bib7]). In addition, PknB interacts with Mur ligases ([@bib29]) and proteins associated with lipid metabolism ([@bib51]). However, the reason for PknB essentiality is currently unknown.

Here, we present multiple facts and results that demonstrate that PknB-depleted *M. tuberculosis* can survive and replicate in osmoprotective medium, suggesting that under these conditions, PknB is not critical for bacterial growth and division. Our findings confirm that CwlM is a major substrate of PknB and demonstrate that phosphorylation determines both the cellular localization and molecular interactions of CwlM in the control of peptidoglycan biosynthesis.

Results {#sec2}
=======

Osmoprotective Medium Supports Growth of PknB-Depleted *M. tuberculosis* {#sec2.1}
------------------------------------------------------------------------

According to previously published data, PknB depletion leads to the cessation of mycobacterial growth and to mycobacterial lysis ([@bib21], [@bib15]), thus precluding any systematic analysis using omics technologies. To overcome this challenge, we developed a special osmoprotective medium and used it to investigate the growth and survival of the previously described *pknB* conditional mutant of *M. tuberculosis*, *pknB*-CM ([@bib15]). In our experiments, the conditional mutant grew in standard 7H9 medium supplemented with pristinamycin, the inducer of *pknB* expression, while the omission of pristinamycin resulted in growth inhibition and in the accumulation of lysed bacteria, consistent with the previous analysis ([@bib15]) ([Figures 1](#fig1){ref-type="fig"}A, 1B, and 1D). Osmoprotective sucrose-magnesium medium (SMM) not only prevented the lysis of the mutant but also supported its growth, even without pristinamycin ([Figures 1](#fig1){ref-type="fig"}A and 1B). Western blot analysis using anti-PknB antibody confirmed that PknB was depleted to \<5% of the original level in media lacking pristinamycin ([Figure 1](#fig1){ref-type="fig"}C), and qRT-PCR analysis showed that *pknB* expression was indeed downregulated 8.6 ± 0.6-fold in pristinamycin-depleted cultures (SMM~−pri~) compared with pristinamycin-supplemented bacteria (SMM~+pri~). SMM~−pri~ *pknB*-CM cells retained pristinamycin-dependent growth in standard media, so they were not escape mutants with uncontrolled *pknB* expression. Furthermore, SMM itself did not significantly influence the growth of *pknB*-CM in the presence of pristinamycin ([Figure 1](#fig1){ref-type="fig"}). Thus, our results demonstrated that the *pknB*-depleted *M. tuberculosis* bacilli were able to survive and grow in SMM. Although the bacteria had a minor growth defect under these conditions, they still reached stationary phase. The *pknB*-CM did not grow on solidified SMM without pristinamycin. *PknB*-CM cells grown in liquid SMM were slightly swollen but showed no significant cellular damage in scanning electron micrographs ([Figure 1](#fig1){ref-type="fig"}D), in contrast to *pknB*-CM bacteria grown in standard medium without pristinamycin. Notably, SMM~−pri~ cells were distinct from the L-forms described for various bacterial species ([@bib13]) and had a properly formed cell envelope ([Figure 1](#fig1){ref-type="fig"}D). To investigate peptidoglycan biosynthesis in the *pknB*-CM, we performed BODIPY FL vancomycin-labeling experiments. Vancomycin binds to the [d]{.smallcaps}-alanine-[d]{.smallcaps}-alanine component of nascent peptidoglycan and is used to label the mycobacterial cell wall ([@bib20], [@bib16]). The *pknB*-CM cells grown in SMM~−pri~ were able to bind BODIPY FL vancomycin, indicating the production of nascent peptidoglycan ([Figure 1](#fig1){ref-type="fig"}E).Figure 1Osmoprotective Medium Supports Growth of a Conditional *pknB* Mutant(A--E) *M. tuberculosis* mutant was grown in standard 7H9 medium with (7H9~+pri~) or without (7H9~−pri~) pristinamycin or in sucrose-magnesium medium with (SMM~+pri~) or without (SMM~-pri~) pristinamycin at 37°C with shaking. Growth was monitored by (A) measurement of optical density at 580 nm and by (B) assessment of colony-forming unit (CFU) counts on 7H10 agar. Data are represented as means ± SEMs (n = 6).(C) PknB was detected using anti-PknB antibody; relative intensity of PknB bands presented as means ± SEMs (n = 3).(D) Scanning electron micrographs of *M. tuberculosis* bacteria.(E) Detection of nascent peptidoglycan by Van-BODIPY labeling. Scale bars, 1 μm.

In summary, our osmoprotective medium supports the growth of PknB-depleted mycobacteria, thus providing a useful tool for investigating the role of PknB in mycobacterial biology and enabling us to conduct phosphoproteomic analyses of PknB-producing and PknB-depleted *M. tuberculosis*.

PknB Depletion Leads to Global Changes in Protein Phosphorylation {#sec2.2}
-----------------------------------------------------------------

A comparative analysis of phosphoproteins from PknB-depleted (SMM~−pri~) and PknB-producing (SMM~+pri~) *M. tuberculosis* cultures revealed global changes in phosphorylation patterns ([Table S1](#mmc2){ref-type="supplementary-material"}). The depletion of PknB resulted in the increased phosphorylation of various proteins, including serine/threonine protein kinase PknA. Other abundant phosphoproteins in the SMM~−pri~ cultures were ribosomal proteins, heat shock proteins, transporters, and factors involved in cell division. Several previously annotated PknB substrates such as MurJ (also known as MviN) ([@bib16]), FhaA ([@bib38]), and GarA ([@bib46]) that control peptidoglycan biosynthesis and central metabolism showed increased phosphorylation in the PknB-depleted samples ([Table S1](#mmc2){ref-type="supplementary-material"}). In addition, phosphorylated MtrA and PrrA, two component response regulators essential for *M. tuberculosis* growth ([@bib53], [@bib18]), were more abundant in the PknB-depleted cultures.

To identify potential PknB-specific substrates, we analyzed phosphopeptides that were enriched in SMM~+pri~ cultures relative to SMM~−pri~ cultures. In total, 13 proteins were found to be \>2-fold more phosphorylated in SMM~+pri~ samples; 6 of them had been previously annotated as proteins essential or advantageous for *M. tuberculosis* growth ([@bib11]) ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc2){ref-type="supplementary-material"}). As expected, PknB was the most phosphorylated protein in PknB-producing *M. tuberculosis.* Other substrates with increased phosphorylation included CwlM, a peptidoglycan amidase homolog ([@bib7]); the annotated enzymes, UvrA, an exonuclease ([@bib37]), and FadE10, an acyl-dehydrogenase; transcriptional regulators Lsr2 ([@bib3]) and EthR ([@bib25]); an RNA-binding protein, RpsC, which is involved in translation initiation; secretion and membrane proteins EspI ([@bib54]) and Rv2397c ABC transporter; and conserved proteins of unknown function, Rv2406c and Rv2908. Most proteins had one phosphosite; however, PknB itself, CwlM, and EspI were phosphorylated on several amino acids.Table 1Peptides with Increased Phosphorylation in PknB-Producing *M. tuberculosis*ProteinGeneFunctionEssential Y/NIdentified Phosphopeptides[a](#tblfn1){ref-type="table-fn"}Fold Change[P]{.ul}knB*Rv0014c*serine/threonine protein kinaseYTSLLSSAAGNLSGPR**T**DPLPR33.50AIADSGNSVTQ**T**AAVIGTAQYLSPEQAR10.40AIAD**S**GNSVTQTAAVIGTAQYLSPEQAR6.11UvrA*Rv1638*exonucleaseNFLAEVVGGGASAA**T**SR5.21EspI*Rv3876*secretion protein EspINRVHPDLAAQHAAAQPD**S**ITAA**T**TGGR4.43VHPDLAAQHAAAQPDSI**T**AA**T**TGGR2.2Rv2406c*Rv2406c*conserved proteinNMGELEAEQQQLQ**S**YITQG3.9CwlM*Rv3915N*-acetyl-muramyl-[l]{.smallcaps}-alanine amidase homologYNDRP**T**GTFTFAELLAHELSVER3.83NDRPTGTF**T**FAELLAHELSVER3.82RodA*Rv0017c*cell division proteinNSPITAAG**T**EVIERV3.03Lsr2*Rv3597*H-NS-like proteinAG[b](#tblfn2){ref-type="table-fn"}IPADVIDAYHAA**T**2.53TrxB1*Rv1471*thioredoxinNAYEVEAGEAT**T**QNGR2.45CysA1*Rv2397c*ABC transporterAGGG**T**EAGNLATSMMK2.38EthR*Rv3855*transcription repressorNTTSAA**S**QASLPR2.29RpsC*Rv0707*ribosomal proteinYAAGGEEAAPDAAAPVEAQSTE**S**2.28FadE10*Rv0873*acyl-CoA de hydrogenaseNAQQTQV**T**EEQAR2.27Rv2908cRv2908chypothetical proteinAG**S**AVVVDAVEHLVR2.03[^2][^3][^4]

Among the PknB substrates showing increased phosphorylation, PknB, CwlM, and RpsC represented potential PknB substrates essential for growth. In particular, CwlM, encoded by *rv3915*, was the most highly phosphorylated essential protein (after PknB itself) in the PknB-producing *M. tuberculosis* compared with the PknB-depleted mycobacteria. We therefore focused our investigation on this target. Four phosphosites were detected in CwlM (threonine 42 \[T42\], T43, T382, and T386); however, only two of these (T382 and T386) were more phosphorylated in the PknB-producing mycobacteria ([Table 1](#tbl1){ref-type="table"}; [Figure S1](#mmc1){ref-type="supplementary-material"}).

PknB was able to phosphorylate *M. tuberculosis* CwlM *in vitro* ([Figure S1](#mmc1){ref-type="supplementary-material"}). Mass spectrometry analysis of *in vitro* phosphorylated CwlM confirmed phosphorylation of T43, T382, and T386, and identified two additional phosphorylated residues, T94 and T384. Similarly, [@bib7] have recently reported that PknB phosphorylates *M. tuberculosis* CwlM *in vitro*. The biological importance of CwlM phosphorylation at these sites was further investigated in complementation studies.

A Phosphoablative CwlM Mutant of *M. tuberculosis* Mimics the Phenotype of PknB-Depleted Mycobacteria {#sec2.3}
-----------------------------------------------------------------------------------------------------

We reasoned that if CwlM is the main substrate of PknB, a phosphoablative mutant of CwlM should reproduce the major features of the PknB-depleted mycobacteria. We first generated a *cwlM* conditional mutant of *M. tuberculosis* (*cwlM*-CM) using the pristinamycin-inducible system. As expected, the mutant did not grow without pristinamycin in liquid ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B) or on solid ([Figure S2](#mmc1){ref-type="supplementary-material"}C) media. Western blot analysis using a CwlM-specific antibody confirmed the near-complete depletion of CwlM in the *cwlM*-CM mutant upon the withdrawal of pristinamycin ([Figure S2](#mmc1){ref-type="supplementary-material"}D). CwlM depletion resulted in severe cell aggregation, the accumulation of lysed mycobacteria ([Figure S2](#mmc1){ref-type="supplementary-material"}D), and the cessation of BODIPY FL vancomycin incorporation ([Figure S2](#mmc1){ref-type="supplementary-material"}F).

This dramatic phenotype could be fully complemented by the reintroduction of *cwlM* with a putative upstream promoter in an integrating plasmid, pMV306. The complemented mutant (*cwlM*-CM~WT~) was able to grow in liquid and solid media without pristinamycin, while a strain with an empty pMV306 plasmid (*cwlM*-CM~pmv306~) displayed the CwlM depletion phenotype ([Figure 2](#fig2){ref-type="fig"}). A panel of site-directed mutants was generated ([Table S2](#mmc1){ref-type="supplementary-material"}) to study the importance of phosphorylation at the different threonine sites. The growth patterns of the resultant *M. tuberculosis* strains are summarized in [Table S3](#mmc1){ref-type="supplementary-material"}. Single replacements of T42, T43, T94, T384, or T386 ([Figure S3](#mmc1){ref-type="supplementary-material"}A) with an alanine did not have a significant effect on *M. tuberculosis* growth. However, mycobacteria expressing the T382A variant could not grow without pristinamycin either in liquid medium ([Figure 2](#fig2){ref-type="fig"}A) or on agar ([Figure 2](#fig2){ref-type="fig"}C), highlighting the T382A mutation as being critical for growth. The replacement of T382 with an aspartate residue (T382D) to mimic phosphorylation resulted in a milder growth defect ([Figures 2](#fig2){ref-type="fig"}A and 2C), while replacement of any other phosphosites with an aspartate had no marked effect on *M. tuberculosis* growth ([Table S3](#mmc1){ref-type="supplementary-material"}; [Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 2T382A Mutant Mimics Phenotype of PknB-Depleted *M. tuberculosis*(A--D) The *cwlM* conditional mutant of *M. tuberculosis* was transformed with pMV306 plasmids containing *cwlM* variants. The resultant strains were grown in 7H9 medium (A) or in SMM (B) without pristinamycin. All of the strains grew similarly when 7H9 or SMM were supplemented with pristinamycin (data not shown for clarity). pMV, *cwlM*-CM~pmv306~ (the empty plasmid control); CwlM, *cwlM*-CM~WT~; T382A and T382D phosphoablative and phosphomimetic mutants, respectively. Data are represented as means ± SEMs (n = 6).(C) Growth of strains on 7H10 agar.(D) Western blot of CwlM variants detected with anti-CwlM antibody.See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"} and [Table S3](#mmc1){ref-type="supplementary-material"}.

A double phosphoablative mutation (T382A and T386A) was very toxic to *M. tuberculosis*, and no transformants could be recovered with this construct. The corresponding double phosphomimetic mutation (T382D+T386D) was not toxic for mycobacteria, but it did not complement the mutant phenotype ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These findings suggest that phosphorylation of both threonines is important for *M. tuberculosis* growth.

We next investigated whether the phosphoablative T382A version of *cwlM*-CM could grow in osmoprotective medium. *CwlM-*CM and *cwl*M-CM~pmv306~ strains did not grow in SMM ([Figure 2](#fig2){ref-type="fig"}B), while the *cwlM*-CM~WT~ and the T382D phosphomimetic grew similarly in standard and SMM ([Figures 2](#fig2){ref-type="fig"}A and 2B). Furthermore, the T382A variant was able to grow in SMM~−pri~ ([Figure 2](#fig2){ref-type="fig"}B) and to incorporate BODIPY FL vancomycin (data not shown), thus mimicking the phenotype of the PknB-depleted *M. tuberculosis*. As demonstrated in [Figure 2](#fig2){ref-type="fig"}D, all of the variant proteins were produced at similar levels. Attempts to complement the *pknB*-CM mutant with any of the phosphomimetic forms were unsuccessful.

CwlM Is Present in Two Distinct Forms during Mycobacterial Growth {#sec2.4}
-----------------------------------------------------------------

The phenotypes of PknB-depleted and CwlM-depleted mycobacteria, as well as those of the phosphoablative and phosphomimetic CwlM *M. tuberculosis* mutants in the present study, suggest that both phosphorylated and non-phosphorylated forms of CwlM play important roles in mycobacterial growth. We hypothesized that the phosphorylated and non-phosphorylated forms may have different cellular localizations. To test our hypothesis, we performed cell fractionation for western blot analysis and investigated the presence of CwlM in *cwlM*-CM and *pknB*-CM samples. As shown in [Figure 3](#fig3){ref-type="fig"}, CwlM was detected in both the cytoplasmic and membrane fractions of *cwlM*-CM~WT~ ([Figure 3](#fig3){ref-type="fig"}A, wild-type \[WT\]) and of pristinamycin-induced *pknB*-CM ([Figure 3](#fig3){ref-type="fig"}B, 7H9~+pri~ and SMM~+pri~). Similar results were obtained in WT *M. tuberculosis* and *M. smegmatis* ([Figure S4](#mmc1){ref-type="supplementary-material"}). Both forms were missing in the control *cwlM*-CM~pmv306~ grown without pristinamycin ([Figure 3](#fig3){ref-type="fig"}A). The T382A form was present in the membrane fraction but not in the cytoplasmic fraction, while the T382D phosphomimetic was present in both fractions, with a slight reduction in the membrane fraction. Furthermore, PknB depletion resulted in the loss of cytoplasmic but not of membrane CwlM ([Figure 3](#fig3){ref-type="fig"}B). Both forms of CwlM were detectable only during the exponential growth phase ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 3PknB-Mediated Phosphorylation of T382 Determines Distribution of CwlM in Cytoplasmic and Membrane Fractions of *M. tuberculosis*(A--D) Lysates obtained from *cwlM*-CM grown in SMM without pristinamycin to prevent induction of genomic *cwlM* (A and C) or from *pknB*-CM grown in SMM or standard 7H9 medium with or without pristinamycin (B and D) were fractionated and probed with anti-CwlM antibodies (A and B) or with anti-T382-P and anti-T382 antibodies (C and D). Anti-GarA and Anti-GlnA antibodies were used to confirm the purity of mycobacterial fractions.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Our complementation data suggested that the phosphorylation of T382 by PknB is critical for *M. tuberculosis* growth in standard media. To detect the phosphorylation state of CwlM in *M. tuberculosis* fractions, we generated phosphosite-specific antibodies. Two different antibodies were used. The first antibody was raised against a peptide containing the phosphorylated form of T382, designated as anti-T382-P antibody, and the second was raised against an equivalent non-phosphorylated peptide, designated as anti-T382 antibody. Western blot analysis using anti-T382-P and *M. tuberculosis* lysates indicated that phosphorylated CwlM was present only in the cytoplasm of *cwlM*-CM~WT~ ([Figure 3](#fig3){ref-type="fig"}C). The T382A and T382D mutants were not phosphorylated, while *cwlM*-CM~pmv306~ did not produce CwlM. Consistent with these findings, non-phosphorylated CwlM was not detected in the cytoplasm, but instead WT T382, T382A, and T382D forms were present in the membrane fractions ([Figure 3](#fig3){ref-type="fig"}C). Furthermore, the T382 phosphorylated CwlM was mainly detected in the cytoplasm of pristinamycin-induced *pknB*-CM, but it was significantly reduced in PknB-depleted mycobacteria ([Figure 3](#fig3){ref-type="fig"}D). Non-phosphorylated CwlM was detected in the membrane fractions of *pknB*-CM under all of the conditions tested ([Figure 3](#fig3){ref-type="fig"}D). These results suggest that in growing bacteria, CwlM is present as both phosphorylated and non-phosphorylated forms. The cytoplasmic form is phosphorylated, whereas the membrane-associated form is non-phosphorylated. In addition, PknB controls the distribution of CwlM via the phosphorylation of T382.

Phosphorylated and Non-phosphorylated CwlM Have Different Protein Partners {#sec2.5}
--------------------------------------------------------------------------

It has recently been reported that T382-phosphorylated CwlM interacts with MurA, which is located in the cytoplasm and is the first enzyme in the biosynthesis of peptidoglycan precursors, and stimulates its activity ([@bib7]). Given that CwlM has no predicted transmembrane domains or lipid anchors, it was reasonable to hypothesize that the membrane-associated non-phosphorylated form may interact with other membrane protein(s). To test this possibility, we prepared membrane and cytoplasmic *M. tuberculosis* fractions for immunoprecipitation assays using the anti-CwlM antibody. Several potential partners of CwlM were identified in cytoplasmic and membrane fractions ([Table S4](#mmc1){ref-type="supplementary-material"}). These partners included FhaA, FtsZ, DnaA, Wag31, and the previously described MurA in the cytoplasmic fraction, and MurJ (MviN), FtsE, and CwsA in the membrane fraction.

Mycobacterial protein fragment complementation assays further confirmed that CwlM interacts with FhaA, MurJ, and CwsA ([Figure S5](#mmc1){ref-type="supplementary-material"}). MurJ is an integral membrane protein with proposed lipid II flippase activity based on cellular assays ([@bib40]). Although the purified protein is reported to lack lipid II transport activity ([@bib27]), lipid II binding to MurJ has been detected by native mass spectrometry and factors that influence the interaction of MurJ with lipid II identified ([@bib6]). Mycobacterial MurJ is characterized by unique structural properties; in addition to 14 highly conserved transmembrane helices, it has an intracellular domain of 334 amino acids, designated as MurJ~icd~ ([@bib16]). We considered MurJ~icd~ as the likely CwlM-binding domain and focused our investigation on this domain rather than on the entire protein.

FhaA contains a C-terminal fork head-associated (FHA) domain that interacts with phosphorylated proteins ([@bib38]). MurJ~icd~ and FhaA have been previously shown to interact with each other ([@bib16]), and we were intrigued by the possibility that CwlM may interact with both proteins. We therefore generated recombinant FhaA and MurJ~icd~ and investigated their interaction with both forms of CwlM. Recombinant Wag31 was used as a control. As [Figure 4](#fig4){ref-type="fig"} shows, Wag 31 did not co-precipitate with either CwlM forms, while MurJ~icd~ mainly co-precipitated with non-phosphorylated CwlM. Densitometric analysis of gels from three independent experiments confirmed that 85% ± 6% of MurJ~icd~ was co-precipitated with non-phosphorylated CwlM compared with 12% ± 6% bound to phosphorylated CwlM. FhaA showed the opposite binding pattern, with 84% ± 4% co-precipitating with phosphorylated CwlM and only 19.7% ± 9% with non-phosphorylated CwlM. As shown in [Figure 4](#fig4){ref-type="fig"}D, the CwlM bound to FhaA was phosphorylated on T382, while the CwlM co-immunoprecipitated with MurJ~icd~ was not phosphorylated.Figure 4PknB Phosphorylation Controls the Interaction of CwlM with MurJ~ICD~ and FhaA(A--D) PknB-phosphorylated and non-phosphorylated recombinant CwlM was mixed with recombinant FhaA (A), MurJ~ICD~ (B), or Wag31 (C) and incubated with gentle mixing for 30 min. Anti-CwlM immunoglobulin G (IgG) Sepharose (IgG-Seph) was then added and further incubated for 30 min. Proteins bound to Sepharose and unbound material were resolved on SDS-PAGE and stained with Coomassie brilliant blue.(D) Confirmation of CwlM phosphorylation. M, protein markers; +, reagent added; −, flow-through fractions.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc1){ref-type="supplementary-material"}.

CwlM Binding to FhaA Is Driven by T382 Phosphorylation and Increased by T386 Phosphorylation {#sec2.6}
--------------------------------------------------------------------------------------------

Our phosphoproteomics and complementation studies highlighted the importance of T382 and T386 phosphorylation for *M. tuberculosis* growth. We therefore explored the role of these phosphosites for binding to FhaA, using the recombinant C-terminal domain of FhaA (designated as FHA) and synthetic peptides corresponding to the C-terminal tail of CwlM. These included single phospho-T382 and phospho-T386 peptides, a double phospho-T382 and phospho-T386-peptide, a non-phosphorylated peptide, a double phosphomimetic (T382D and T386D), and double phosphoablative peptides (T382A and T386A). Using two-dimensional nuclear magnetic resonance spectroscopy, we detected chemical shifts in the \[^1^H,^15^N\] heteronuclear single quantum coherence (HSQC) spectra of the ^15^N-labeled FHA domain upon the addition of all of the phosphopeptides, indicating binding ([Figure 5](#fig5){ref-type="fig"}). Differences were observed in the pattern of chemical shift changes in FHA for the two single phosphopeptides. For example, the chemical shifts of T470 and G471 were appreciably more perturbed upon the addition of the T382 phosphopeptide than upon addition of the T386 phosphopeptide, despite the presence of two phenylalanines in positions 385 and 387. This observation indicates that the T386 phosphopeptide may bind more weakly to FHA compared to the binding of the T382 peptide. Perturbations in the \[^1^H,^15^N\] HSQC spectra of the^15^N labeled FHA domain, observed upon the addition of the double phosphopeptide, corresponded to those observed for the single T382 phosphopeptide ([Figure S6](#mmc1){ref-type="supplementary-material"}) but with larger changes in the chemical shifts. T470 and T471 of FHA were again perturbed. These findings suggest that the primary binding site in FHA was occupied by phospho-T382 and that T386 phosphorylation played an accessory role by increasing this interaction but without replacing the phospho-T382 as the main anchor for FHA binding. The additional phosphorylation of other FHA domains has been reported to have a similar effect on protein-protein interactions ([@bib24]). In control experiments, we tested non-phosphorylated and double phosphoablative peptides and did not observe any chemical shift in the FHA spectra, while the double phosphomimetic peptide displayed a weaker binding. The role of T384 phosphorylation in FHA and CwlM interaction was not investigated.Figure 5Amide Averaged Chemical Shift Variations (Δδ) as a Function of Protein Sequence(A--D) Δδ values were calculated between ^1^H-^15^N HSQC spectra recorded at 800 MHz (20°C and pH 6.8) on 80 μM ^15^N-uniformly labeled samples of Rv0020c-FHA before and after addition of 80 μM concentrations of unlabeled peptides pT382--T386 (A), T382--pT386 (B), pT382--pT386 (C), or D382--D386 (D), with Δδ = \[(Δδ~H~)^2^ + (Δδ~N~ × (γ~N~/γ~H~))^2^\]^0.5^.The dotted lines show the SD (0.078 ppm) from the "C" position.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Thus, we can postulate that phosphorylation at the T382 position is critical for the interaction of CwlM with FhaA and that additional phosphorylation potentiates the binding of these two proteins. These data further support our mutant complementation results ([Figure S3](#mmc1){ref-type="supplementary-material"}; [Table S3](#mmc1){ref-type="supplementary-material"}), which together indicate that phosphorylated threonines have distinct roles in CwlM function.

Non-phosphorylated CwlM Interacts with an Essential Part of MurJ~icd~ {#sec2.7}
---------------------------------------------------------------------

We hypothesized that the interaction of CwlM with MurJ could be essential for mycobacterial growth. According to [@bib16], not all MurJ domains are essential for *M. tuberculosis* viability. These authors obtained viable deletion mutants when the protein was truncated at phenylalanine 715; however, shorter truncated MurJ forms did not support mycobacterial growth. These results indicated that the E541--F680 region of MurJ~icd~, which links the 14^th^ transmembrane helix with the pseudokinase domain, may be indispensable for mycobacterial growth, while the non-essential pseudokinase domain (D681--R963) may have a regulatory role via the recruitment of the FHA domain of FhaA ([@bib16]). No function has been described for the E541--F680 region. We therefore tested whether this region can bind to CwlM. We generated a recombinant version of this linker for use in immunoprecipitation experiments. As shown in [Figure S7](#mmc1){ref-type="supplementary-material"}, the linker did indeed bind CwlM. Our attempts to generate a mycobacterial mutant lacking this region were unsuccessful, confirming previously published results on the essentiality of this part of MurJ~icd~ ([@bib16]). Thus, we established that non-phosphorylated CwlM interacts with an essential region of MurJ. The lack of BODIPY FL vancomycin labeling in the CwlM-depleted mycobacteria ([Figure S2](#mmc1){ref-type="supplementary-material"}) indicates that this interaction may be important for the production of nascent peptidoglycan.

Discussion {#sec3}
==========

PknB Is Not Critical for *M. tuberculosis* Growth in Osmoprotective Medium {#sec3.1}
--------------------------------------------------------------------------

PknB-like kinases are widely distributed in Gram-positive bacteria ([@bib33]). Most are not essential for bacterial viability and they fulfill distinct biological functions. For example, in *Bacillus subtilis*, PrkC is not required for growth and regulates spore germination ([@bib39]), while in *Streptococcus pneumoniae*, StkP is important for cell division and cell wall remodeling ([@bib5], [@bib55]). It is widely accepted that PknB is essential for mycobacterial viability ([@bib14]) because of its involvement in regulating peptidoglycan biosynthesis and cell shape ([@bib21]). PknB is produced during exponential growth and its altered expression dramatically affects mycobacterial growth and morphology. PknB depletion leads to the accumulation of elongated cells and to gradual bacterial lysis ([@bib15]), while *pknB* overexpression affects cell viability and morphology ([@bib21]). These effects of dysregulated PknB expression on bacterial viability have precluded a detailed molecular analysis of its essentiality for mycobacterial viability, given that altered phosphoproteomics profiles could be attributed to "dying cells."

In this study, we developed a special medium that prevented the death of PknB-depleted mycobacteria and supported their propagation. The PknB-depleted *M. tuberculosis* bacilli were able to synthesize peptidoglycan and showed only marginal changes in morphology. The need for an osmoprotective medium suggests that the PknB-depleted mutant has defects in peptidoglycan structure and that PknB has a regulatory role in peptidoglycan biosynthesis. We have previously shown that the overexpression of the PknB_PASTA domain partially mimics the phenotypes of *pknB*-depleted mycobacteria by inhibiting mycobacterial growth and causing increased sensitivity to meropenem ([@bib44]), the inhibitor of transpeptidases and [d,d]{.smallcaps}-carboxypeptidase in mycobacteria ([@bib23]). The inhibition of PknB-like kinases in other bacteria also increases bacterial susceptibility to β-lactam antibiotics ([@bib47], [@bib32]), indicating that these kinases may control peptidoglycan biosynthesis. We therefore propose that PknB depletion could result in defective peptidoglycan synthesis, which is incompatible with growth in standard conditions.

CwlM Is a Major PknB Substrate {#sec3.2}
------------------------------

A substantial number of PknB substrates have been identified using *in vitro* phosphorylation assays ([@bib35]). Several phosphoproteomics studies have also demonstrated a high abundance of phosphoproteins in mycobacteria (e.g., [@bib36]); however, there is limited information about the specific kinases that are responsible for the phosphorylation of these proteins. One study attempted to identify PknB substrates in a strain overexpressing PknB at early stationary phase ([@bib21]), while a more recent investigation analyzed phosphopeptides from *M. tuberculosis* treated with kinase inhibitors compared to untreated controls ([@bib9]).

Here, we conducted a comparative phosphoproteomics analysis of PknB-producing and PknB-depleted mycobacteria in the exponential growth phase and identified potential PknB substrates. This analysis identified CwlM as being the strongest candidate for a main PknB substrate. CwlM is essential for growth and is likely to be involved in the regulation of cell wall biosynthesis. A recent study ([@bib7]) reported that PknB phosphorylates CwlM *in vitro* and that a T374 phosphoablative CwlM mutant of *M. smegmatis* had a severe growth defect in liquid and solid media. These authors' genetic and biochemical evidence suggests that phosphorylated CwlM stimulates the activity of MurA, the first enzyme in the biosynthesis of peptidoglycan precursors, and that it is therefore likely to be directly involved in the regulation of peptidoglycan precursor production. Our findings confirm that this regulation is not essential under osmoprotective conditions.

Our study also demonstrated that the phosphorylation of T382 in CwlM is critical for *M. tuberculosis* growth in standard but not in osmoprotective media. This remarkable similarity between the phenotypes of PknB-depleted and phosphoablative-CwlM mycobacteria, together with the direct demonstration of dramatically decreased levels of phosphorylated CwlM in the PknB-depleted strain, suggests that CwlM phosphorylation may explain why PknB is essential for *M. tuberculosis* viability. However, the phosphorylation of other PknB substrates may also be critical for *M. tuberculosis* viability under certain conditions.

Phosphorylated and Non-phosphorylated CwlM Proteins Have Distinct Cell Localizations and Different Protein Partners {#sec3.3}
-------------------------------------------------------------------------------------------------------------------

Our results indicate that both phosphorylated and non-phosphorylated forms of CwlM have distinct roles in *M. tuberculosis* growth. CwlM-depleted mycobacteria cannot neither grow in osmoprotective SMM nor incorporate BODIPY FL vancomycin, while the phosphoablative mutant can grow in SMM and incorporate BODIPY FL vancomycin. We were puzzled by the potential roles of the two CwlM forms and investigated whether phosphorylation regulates the distribution of CwlM. We established that the phosphorylated CwlM form was mainly present in the cytoplasm of PknB-producing mycobacteria and was minimally detectable in the PknB-depleted *M. tuberculosis*. In contrast, the non-phosphorylated form was associated with the membrane; the T382A phosphoablative form of CwlM was found exclusively in the membrane and the phosphomimetic form was present predominantly in the cytoplasm of *cwlM*-CM. Our data suggest that the substitution of T382 with a negatively charged amino acid (T382D) does not fully mimic phosphorylated CwlM. Instead, CwlM T382D possessed properties of both the phosphorylated and non-phosphorylated forms, which explains how this CwlM form could complement the *cwlM*-CM but not the *pknB*-CM of *M. tuberculosis*. These results imply that a balance needs to be maintained between the phosphorylated and non-phosphorylated forms of CwlM and that this fine balance is essential for bacterial viability and can be affected by altered PknB expression or activity.

CwlM is predicted to be an *N*-acetylmuramoyl-[l]{.smallcaps}-alanine amidase; however, its actual activity remains uncertain. While [@bib12] have previously demonstrated CwlM to possess peptidoglycan hydrolyzing activity, in a more recent study, no such activity was detected, presumably due to the lack of two essential catalytic residues ([@bib7]). As mentioned above, [@bib7] have proposed that phospho-CwlM controls peptidoglycan generation by activating MurA; however, the possible functions of non-phosphorylated CwlM were not addressed. Previously published kinetic parameters do not support the activation of MurA by non-phosphorylated CwlM ([@bib7]). Moreover, *cwlM* could not be deleted in an *M. smegmatis* strain with an *murA* S368P mutation that rescued the growth defect of a phosphoablative *cwlM* mutant ([@bib7]).

In this study, we show that non-phosphorylated CwlM interacts with the essential linker region (E541--F680) of the proposed lipid II flippase, MurJ. Furthermore, phosphorylated CwlM does not interact with MurJ but instead binds to FhaA. CwlM-depleted mycobacteria did not incorporate BODIPY FL vancomycin and had a severe shape defect that can be attributed to impaired peptidoglycan biosynthesis ([Figure S2](#mmc1){ref-type="supplementary-material"}). In mycobacteria, MurJ has an additional intracellular region that includes a pseudokinase domain (KHD) ([@bib16]). KHD is phosphorylated by PknB to produce a complex with FhaA, but the precise role of this complex is not fully understood. Previously published data showed that the depletion of FhaA increased the incorporation of labeled vancomycin into peptidoglycan and that PknB overexpression had an opposite effect, increasing the accumulation of diaminopimelate (DAP)-containing precursors in the cytoplasm ([@bib16]). It has been therefore proposed that PknB phosphorylation downregulates MurJ flippase activity ([@bib16]). This potential regulatory mechanism is, however, non-essential for bacterial growth because FhaA and the pseudokinase domain of MurJ (D681--E955) could be inactivated without having any impact on mycobacterial viability ([@bib16]).

We hypothesize that the binding of non-phosphorylated CwlM to the essential MurJ linker region is necessary for the function of MurJ, perhaps by facilitating the transport of lipid II across the membrane and activating peptidoglycan polymerization ([Figure 6](#fig6){ref-type="fig"}A). The nascent peptidoglycan is polymerized and incorporated into the existing cell wall during growth and cell division ([@bib45]). This incorporation may be delayed under certain conditions, for example, when cell growth slows or when an efficient peptidoglycan synthesis complex causes peptidoglycan material to accumulate near the cell membrane, potentially interfering with other cell envelope processes. It was previously proposed that the PASTA domain of PknB senses uncrosslinked peptidoglycan ([@bib52]). The PASTA domain may thus bind such excessive peptidoglycan material ([Figure 6](#fig6){ref-type="fig"}B), resulting in the autophosphorylation and activation of PknB ([@bib4]), followed by the phosphorylation of CwlM and MurJ. In this scenario, the phosphorylated CwlM dissociates from MurJ and interacts with FhaA. Thus, PknB-mediated phosphorylation may control MurJ activity by two independent mechanisms: (1) by phosphorylating CwlM and preventing its interaction with MurJ and (2) by phosphorylating MurJ and inhibiting its activity. FhaA may serve as a regulatory hub to ensure that a balance is maintained between phosphorylated and non-phosphorylated CwlM and to regulate the interactions between CwlM and its partners, MurJ and MurA.Figure 6Proposed CwlM-Mediated Regulation of Peptidoglycan Synthesis in Mycobacteria(A) In this model, non-phosphorylated CwlM interacts with the essential MurJ linker region and activates or facilitates the transport of peptidoglycan precursors. This activity may lead to the accumulation of excessive amounts of peptidoglycan, which is not incorporated into the cell wall.(B) The PASTA domain of PknB senses uncrosslinked peptidoglycan, resulting in the autophosphorylation and activation of PknB. PknB then phosphorylates CwlM and MurJ, which both interact with FhaA. Phosphorylated CwlM also interacts with MurA (not included for clarity). FhaA may serve as a regulatory hub to ensure that a balance is maintained between the phosphorylated and non-phosphorylated forms of CwlM and that interactions between CwlM and its partners, MurJ and MurA, are regulated. The red P shows phosphorylation of PknB, CwlM, and MurJ.

This PknB-mediated regulation perhaps supports the unique asymmetrical polar growth and peptidoglycan biosynthesis in mycobacteria ([@bib20]). Mycobacteria lack many important components to maintain cell shape, such as MreB ([@bib19]), and require properly matured peptidoglycan to preserve their rod-like shape and cell wall integrity ([@bib2]).

Although the precise function and importance of the CwlM-MurJ interaction remain to be established, our data suggest that a distinct mechanism exists for the regulation of peptidoglycan synthesis in mycobacteria. The activation of MurJ by CwlM poses a significant technical challenge to demonstrate directly, because the possible flippase activity of MurJ has not been detected *in vitro*. CwlM may also be involved in the regulation of other cellular processes (e.g., via its interaction with CwsA) or it may possess other enzymatic activity. Future studies will thus help to establish the exact molecular mechanisms that underlie the essential role of CwlM in mycobacteria.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Phospho-Threonine Antibody (P-Thr Polyclonal)Cell Signaling TechnologyCat\#9381, RRID:[AB_330301](nif-antibody:AB_330301){#intref0010}Monoclonal Anti-polyHistidine antibody produced in mouseSigma-AlrdichCat\#H1029, RRID:[AB_260015](nif-antibody:AB_260015){#intref0015}Monoclonal Anti-*M. tuberculosis* GlnA (Gene Rv2220), Clone IT-58BEI ResourcesNR-13656Monoclonal Anti-*M. tuberculosis* GroEL2 (Gene Rv0440), Clone IT-70BEI ResourcesNR-13657Anti-PknB antibody raised in rabbit[@bib15]N/ACustom anti-GarA antibody raised in rabbitCambridge Biosciences provided by H O'HareN/ACustom polyclonal anti-CwlM antibody raised in rabbitThermo Fisher ScientificN/ACustom polyclonal antibodies raised against GKNDRPT-phosphoGT in rabbit (anti-T382-P)Gemini Biosciences LtdN/ACustom polyclonal antibody raised against GKNDRPTGT in rabbit (anti-T382)Gemini Biosciences LtdN/AAnti-Mouse IgG (whole molecule) −Alkaline Phosphatase antibody produced in rabbitSigma-AldrichCat\# A3562; RRID:[AB_258091](nif-antibody:AB_258091){#interref0010}Mouse Anti-Rabbit IgG Antibody: APAviva Systems Biology via GeneronCat\# OASB00822Anti-rabbit IgG, HRP-linked AntibodyCell Signaling TechnologyCat\#7074; RRID:[AB_2099233](nif-antibody:AB_2099233){#interref0015}**Bacterial and Virus Strains***Mycobacterium tuberculosis* H37RvLaboratory stockATCC 27294*Mycobacterium smegmatis* mc^2^155Laboratory stockATCC 700084*Mycobacterium tuberculosis* H37Rv conditional PknB mutant[@bib15]N/A*Mycobacterium tuberculosis* H37Rv conditional CwlM mutantThis studyN/A*Mycobacterium tuberculosis* H37Rv conditional CwlM complemented mutants (detailed in [Table S2](#mmc1){ref-type="supplementary-material"})This studyN/A*Mycobacterium smegmatis* mc^2^155 M-PFC strains (detailed in [Table S2](#mmc1){ref-type="supplementary-material"})This studyN/A*Escherichia coli* α-Select Gold Competent CellsBIOLINEBIO-85027*Escherichia coli* OverExpress C41 (DE3) Chemically Competent CellsLucigenCat\#60442-1*Escherichia coli* OverExpress C41 (DE3) strains for overexpression of recombinant proteins (detailed in [Table S2](#mmc1){ref-type="supplementary-material"})This studyN/A**Chemicals, Peptides, and Recombinant Proteins**BD Difco Dehydrated Culture Media: Middlebrook 7H9 BrothFisher Scientific*Cat\#DF0713-17-9*BD Difco Dehydrated Culture Media: Middlebrook 7H10 AgarFisher Scientific*Cat\#DF0627-17-4*Hygromycin B (50 mg/ml)ThermoFisher ScientificCat\#10687010PristinamycinMolcanCat\# PSM01A-100cOmplete Ultra Tablets Protease Inhibitor CocktailSigma-Aldrich*05892970001 ROCHE*PhosSTOP phosphatase inhibitor tabletsSigma-Aldrich*PHOSSRO ROCHE*Ni-NTA agaroseQIAGENCat\#30210Glutathione Sepharose 4B GST-tagged protein purification resinGE Healthcare Life SciencesCat\#17075601HiLoad 16/600 Superdex 200 pg prepacked columnGE Healthcare Life SciencesCat\#28989335Cyanogen bromide-activated-Sepharose 4BSigma-AldrichCat\#C9210AC-NDRPTGTFTFAELLA-NH2 peptideGeneronCustom synthesizedAC-NDRPT(phospo)GTFT(phospo)FAELLA-NH2GeneronCustom synthesizedAC-NDRPT(phospho)GTFTFAELLA-NH2GeneronCustom synthesizedAC-NDRPTGTFT(phospho)FAELLA-NH2GeneronCustom synthesizedAC-NDRPAGTFAFAELLA-NH2GeneronCustom synthesizedAC-NDRPDGTFDFAELLA-NH2GeneronCustom synthesizedSERVA Gel TG Prime 4-20% 10 samples wellsGeneronCat\# 43277.01SERVA Gel TG Prime 12% 12 samples wellsGeneronCat\# 43266.01SIGMAFAST BCIP/NBTSigma-AldrichCat\#5655BODIPY FL VancomycinThermoFisher Scientific*Cat\# V34850*Trizol LS ReagentThermoFisher Scientific*Cat\#10296010*Recombinant 6xHis-tagged CwlMThis study*N/A*Recombinant 6XHis-tagged MurJ ICDThis study*N/A*Recombinant 6xHis-tagged 6xHis-MurJ~E541-F680~This study*N/A*Recombinant GST-tagged FhaAThis study*N/A*Rv0020c_FHA domain[@bib38]*N/A*Recombinant GST-tagged Wag31This study*N/A***Critical Commercial Assays**GenElute Plasmid Miniprep kitSigma-Aldrich*Cat\# PLN350*QIAquick Gel Extraction KitQIAGENCat\# 28706QIAquick PCR Purification KitQIAGENCat\# 28106GeneArt Site-Directed Mutagenesis PLUS SystemThermoFisher Scientific*Cat\#A14604*Turbo DNA-free kitThermoFisher Scientific*Cat\#AM1907*SuperScript Reverse Transcriptase IIThermoFisher Scientific*Cat\#18064022*Absolute QPCR SYBR Green mixThermoFisher Scientific*Cat\#AB4322B*Platinum *Taq* DNA polymeraseThermoFisher Scientific*Cat\# 10966034*Restriction enzymesNew England Biolabs(UK) Ltd- /Cat \#R3193S; R3182L; R0111L; R3136L; R3142LLigaFast Rapid DNA Ligation SystemPromegaCat\# M8221SignalFire Elite ECL ReagentCell Signaling TechnologyCat\#12757STitansphere Phos-TiO KitGL SciencesCat\# 5010-21311**Deposited Data**Raw and analyzed phosphoproteomics dataProteomeXchange Consortium via the PRIDEPXD009239 and 10.6019/PXD009239**Oligonucleotides**Oligonucleotides were custom synthesized (details provided in [Table S4](#mmc1){ref-type="supplementary-material"})Sigma AldrichN/A**Recombinant DNA**Purified Genomic DNA from NR-13648 *M. tuberculosis* Strain H37RvBEI-ResourcesNR-48669Mycobacterial protein fragment complementation (M-PFC)[@bib41]N/AIntegrating plasmid pMV306[@bib1]N/ApAZI9479 suicide vector.[@bib15]N/ApET15bTEV[@bib8]N/AGST-tagged PknB-(1-331)[@bib28]N/A**Software and Algorithms**Xcalibur softwareThermoFisher ScientificVersion 2.0 SR2 Core, RRID:[SCR_014593](rridsoftware:SCR_014593){#intref0020}Progenesis LC-MS softwareNonlinear Dynamics [@bib17]Version 2.4, NonlinearMASCOTMatrix Science, London, UKVersion 2.2.04, RRID:[SCR_014322](rridsoftware:SCR_014322){#intref0025}Scaffold Q+Proteome Software Inc., Portland, ORVersion 4.8.1Proteome DiscovererThermo ScientificVersion 1.4.1.14, RRID:[SCR_014477](rridsoftware:SCR_014477){#intref0030}X!TandemThe GPM, [thegpm.org](http://thegpm.org){#intref0035}Version CYCLONE 2010.12.01.1, RRID:[SCR_015645](rridsoftware:SCR_015645){#intref0040}

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Galina V. Mukamolova (<gvm4@leicester.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

*M. tuberculosis* and *M. smegmatis* were grown in Middlebrook 7H9 liquid medium supplemented with 10% (v/v) Albumin-Dextrose Complex (ADC), 0.2% (v/v) glycerol and 0.1% (w/v) at 37°C with shaking at 100 rpm. Antimicrobials were added at the following concentrations (μg/ml): hygromycin 50; kanamycin 50; pristinamycin 0.5; trimethoprim 15. Sucrose magnesium medium (SMM) contained 0.3 M sucrose, 20 mM MgSO~4~, 0.1% Tween 80 (w/v), 10% (v/v) ADC in standard 7H9 broth. Bacterial growth was followed by measurement of absorbance at 580 nm, using a spectrophotometer, or by colony-forming unit (CFU) counting on 7H10 agar.

Methods Details {#sec4.4}
---------------

### Generation of M. tuberculosis mutants {#sec4.4.1}

To generate *cwlM*-CM, a 5′-prime fragment of the *cwlM* gene (800 bp) from *M. tuberculosis* was amplified using primers CMRv3915F and CMRv3915R for *M. tuberculosis* ([Table S5](#mmc1){ref-type="supplementary-material"}). This fragment was cloned into *NcoI* and *SphI* sites of the pAZI9479 plasmid. Transformants were selected on 7H10 agar containing hygromycin and pristinamycin. Single crossovers were confirmed by PCR using primers FG2224 and FG3106.

For *cwlM*-CM complementation, a coding sequence of *Rv3915* (*cwlM*) with a 200 bp-upstream region was amplified from the *M. tuberculosis* genome using primers Rv3915pMV306F2 and Rv3915pMV306R1. The resulting fragment was cloned into the KpnI and HindIII sites of the pMV306 plasmid. Transformants were selected on 7H10 medium containing hygromycin, kanamycin and pristinamycin. CwlM variants were obtained using a GeneArt Site-Directed Mutagenesis System and the primers used are listed in [Table S5](#mmc1){ref-type="supplementary-material"}. All constructs were sequenced by GATC Biotech before further applications.

### Peptidoglycan labeling and microscopy {#sec4.4.2}

*M. tuberculosis* cells were incubated with a mixture of vancomycin and BODIPY FL vancomycin for 24 hours with shaking at 37°C. Mycobacteria were washed with PBS and fixed in 2% (w/v) paraformaldehyde in PBS for 24 hours before imaging using a 12/10bit, high-speed Peltier-cooled CCD camera (FDI, Photonic Science) using Image-Pro Plus (Media Cybernetics) software.

For scanning electron microscopy (SEM), mycobacteria from exponential phase were washed in PBS before fixation in 2.5% glutaraldehyde in PBS for 24 hours at room temperature. After further PBS washes, cells were dispensed onto a poly-[l]{.smallcaps}-lysine coated glass slide, before further fixation with 1% aqueous osmium tetroxide at room temperature. Extensively washed glass slides were mounted onto aluminum stubs, coated with gold/palladium in a Quorum Q150 TES coating unit, and were then imaged using a Hitachi S3000H SEM with an accelerating voltage of 10kV.

### Transcriptional Profiling {#sec4.4.3}

Total RNA was isolated from 10 mL of mycobacterial cultures using the Trizol reagent, and cDNA samples were generated using Superscript Reverse Transcriptase II and gene-specific primers. Q-PCR was performed in a Corbett Rotor Gene 6000 real time thermocycler using Absolute QPCR SYBR Green mix, as described previously ([@bib44]).

### Mycobacterial protein fragment complementation assay {#sec4.4.4}

Genes of interest were amplified from the *M. tuberculosis* genome and were cloned in corresponding plasmids. *CwlM* was cloned in pUAB100 (replacing the GCN4 leucine zipper domain) and in pUAB300 ([@bib41]) to generate fusion proteins with dihydrofolate reductase domains. Full length *dnaA, fhaA, ftsE, ftsZ*, *cwsA* and *murJicd* were cloned in pUAB200 (replacing the GCN4 leucine zipper domain) and pUAB400 plasmids. *M. smegmatis* transformants were spotted on 7H10 plates supplemented with hygromycin, kanamycin and trimethoprim.

### Mycobacterial cell fractionation {#sec4.4.5}

Mycobacteria were lysed in a Minilys homogenizer (Bertin Instruments) using glass beads in TBS buffer containing 20 mM TrisCl, pH 8.0, 150 mM NaCl, 20 mM KCl, 10 mM MgCl~2~, and proteinase/phosphatase inhibitors. Lysates were centrifuged at 27,000 x *g* for 1 hour (pellets discarded), followed by 4-hour centrifugation at 100,000 x *g*. The supernatants contained cytoplasmic proteins (cytoplasmic fraction); the pellets (membrane fractions) were washed once in carbonate buffer, pH 11 and twice in TBS buffer. Proteins from cellular fractions were separated on SDS-PAGE. The purity of fractions was confirmed by the detection of diagnostic proteins, GarA (cytoplasmic protein) and GlnA (membrane protein).

### Isolation of recombinant proteins {#sec4.4.6}

*CwlM*, *murJicd, murJ*~*E541-F680*~, *fhaA, wag31* were amplified from the *M. tuberculosis* genome using corresponding primers ([Table S2](#mmc1){ref-type="supplementary-material"}) and were cloned either in pET15-TEV (*cwlM*, *murJcd, murJ*~*E541-F680*~) or in pGEX2T (*fhaA* and *wag31*). After confirmation by sequencing, the constructs were transformed into *E. coli* OverExpress C41(DE3) competent cells. *E. coli* strains were grown to OD 0.5 and protein expression was induced with 0.5 mM IPTG followed by incubation at 16°C overnight. The recombinant proteins were purified using affinity chromatography and size exclusion chromatography.

### Protein Electrophoresis and Western Blot {#sec4.4.7}

Proteins were separated on 4%--20% gradient SERVA gels and transferred onto a nitrocellulose membrane using a Trans-Blot® Turbo Transfer System (Bio-Rad). SIGMAFAST BCIP®/NBT or SignalFire Elite ECL Reagent were used to visualize proteins on C-DiGit Chemiluminescent Blot Scanner (LI-COR Biosciences), according to the manufacturer's instructions.

### Immunoprecipitation assays {#sec4.4.8}

Anti-CwlM-IgG Sepharose was prepared by cross-linking the anti-CwlM antibody to cyanogen bromide-activated-Sepharose^®^ 4B. For immunoprecipitation assays, cellular fractions (100 μg proteins in 1mL) were mixed with 10 μL of anti-CwlM-IgG-Sepharose and incubated for 60 min on a laboratory rotator, followed by centrifugation for 5 min at 500 x g. Supernatants were removed and the resin pellets were washed 3 times with TBS. Proteins were extracted with 40 μL of phosphoric acid, pH 2.0, dried and used for western blot and mass spectrometry analyses. Cellular fractions from the CwlM-depleted mutant served as a control to detect non-specifically binding or contaminating proteins.

For confirmation of interactions, recombinant CwlM and other proteins (10 μg each) were mixed in phosphate buffer (20 mM KH~2~PO~4~, pH 7.0, 100 mM NaCl, 10 mM KCl) with 10 μL of anti-CwlM-IgG-Sepharose and processed as described above.

### *In vitro* protein phosphorylation by PknB {#sec4.4.9}

Purified recombinant CwlM (10 μM) was mixed with the recombinant catalytic domain of PknB (5 μM) in a kinase buffer (20 mM Tris--HCl, pH 8.0; 0.5 mM DTT; 10 mM MgCl~2~; 0.1 mM ATP) and incubated at 37°C for one hour. To identify phosphorylated residues, trypsin-digested proteins were analyzed using a LTQ-Orbitrap-Velos mass spectrometer.

### Quantitative label-free phosphoproteomics analysis and phosphopeptide quantification {#sec4.4.10}

*PknB*-CM cultures were centrifuged, washed twice in PBS and resuspended in buffer containing 20 mM TrisCl, pH 7.5, 1 M NaCl, 8 M urea, and proteinase/phosphatase inhibitors. After bead beating, lysates were cleared by centrifugation and filtration (0.22 μm) and treated using the FASP protocol, as described previously ([@bib49]). Desalted samples were enriched on TiO~2~ beads ([@bib43]), speed vacuumed to dryness and re-suspended in 1% formic acid. Trypsin-digested peptides were separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system and Acclaim PepMap100 nanoViper C18 trap column (100 μm inner-diameter, 2cm; Thermo Scientific). After trap enrichment, peptides were eluted onto an Acclaim PepMap RSLC nanoViper, C18 column (75 μm, 15 cm; ThermoScientific) with a linear gradient of 2%--40% solvent B (80% acetonitrile with 0.08% formic acid). The HPLC system was coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ-Orbitrap Velos, Thermo Scientific) via a nanoelectrospray ion source (Thermo Scientific). Data were acquired using the Xcalibur software. The acquired spectra (Thermo.raw files) were loaded to the Progenesis LC-MS software (version 2.4, Nonlinear) for label free quantification ([@bib17]). Three biological replicates for each sample were analyzed. Profile data of the MS scans were transformed to peak lists with Progenesis LC-MS using a proprietary algorithm. The database search was performed with MASCOT (version 2.3.2, Matrix Science, London, UK).

### NMR chemical shift mapping {#sec4.4.11}

FHA ^1^H~N~ and ^15^N backbone chemical shift perturbations (Δδ) were measured from ^1^H-^15^N HSQC experiments upon titration with different peptides corresponding to the C-terminal phosphorylated part of CwlM (^378^NDRPTGTFTFAELLA^392^). ^1^H-^15^N HSQC experiments were carried out at 20°C on a Bruker Avance III 800 spectrometer, equipped with 5 mm z-gradient TCI cryoprobe. ^15^N-labeled Rv0020c-FHA domain (80 μM) was dissolved in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, 1 mM Tris-HCl with 5% D~2~O for the lock. Six spectra were recorded by adding 80 μM of six different peptides corresponding to different phosphorylation (p) states of the C-terminal part of CwlM: pT382-T386, T382-pT386, pT382-pT386, T382-T386, A382-A386 and D382-D386. An additional reference spectrum was taken on a FHA sample without peptides. All ^1^H -^15^N HSQC spectra were recorded using a time domain data size of 64 (*t1*) × 1024 (*t2*) complex points, and 16 transients per *t1* increment. For analysis, ^1^H~N~ and ^15^N chemical shift changes were combined using the equation: Δδ = \[(Δδ~H~)^2^ + (Δδ~N~ × (γ~N~/γ~H~))^2^\]^0.5^, where values of Δδ \> 0.078 ppm have been defined as sign.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Analysis of growth ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [S2](#mmc1){ref-type="supplementary-material"}) was done using Microsoft Excel for Mac Version 15.40. N correspond to independent biological replicates.

Quantitative label-free phosphoproteomics analysis and phosphopeptide quantification ([Table 1](#tbl1){ref-type="table"} and [Table S1](#mmc2){ref-type="supplementary-material"}): data were acquired using the Xcalibur software and acquired spectra (Thermo.raw files) were loaded to the Progenesis LC-MS software (version 2.4, Nonlinear) for label free quantification ([@bib17]). Three biological replicates for each sample were analyzed. Profile data of the MS scans were transformed to peak lists with Progenesis LC-MS using a proprietary algorithm. The database search was performed with MASCOT (version 2.3.2, Matrix Science, London, UK).

Densitometric analyses of protein bands ([Figures 1](#fig1){ref-type="fig"} and [4](#fig4){ref-type="fig"}) were done using ImageJ version 1.51 software. Blots or gels from three independent experiments were used. PknB intensity was expressed as percentage of PknB produced in the presence of pristinamycin which corresponds to band 2. Protein abundance bound to anti-CwlM IgG Sepharose was expressed as a percentage of total amount used for immunoprecipitation assays, which corresponds to lane 5 on each gel.

Data and Software Availability {#sec4.6}
------------------------------

Genebank: ASM19595v2 was used for annotation of *M. tuberculosis* proteins (<https://www.ncbi.nlm.nih.gov/assembly/GCF_000195955.2/>).

The accession numbers for the mass spectrometry proteomics data reported in this paper are ProteomeXchange Consortium via PRIDE: [PXD009239](pride:PXD009239){#intref0055} and 10.6019/PXD009239 (<http://www.proteomexchange.org>).

Supplemental Information {#app2}
========================

Document S1. Figures S1--S7 and Tables S2--S5Table S1. Identification of Differentially Phosphorylated Peptides in PknB-Producing and PknB-Depleted *M. tuberculosis* Grown in SMM, Related to Table 1^∗^ A cut-off of 2-fold for significant changes between the PknB-producing and PknB depleted bacteria was chosen. Phosphopeptides with p values (one way ANOVA) \> 0.05 were not included in the table. Phosphorylated residues are shown in bold font.Document S2. Article plus Supplemental Information

The following reagents were obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-*M. tuberculosis* GlnA (Gene Rv2220), Clone IT-58 (CBA5) (produced *in vitro*), NR-13656; Monoclonal Anti-*Mycobacterium tuberculosis* GroEL2 (Gene Rv0440), Clone IT-70 (DCA4) (produced *in vitro*), NR-13657; Genomic DNA from *Mycobacterium tuberculosis*, Strain H37Rv, NR-48669. We acknowledge the Centre for Core Biotechnology Services at the University of Leicester for support with the containment level 3 experiments, the imaging of *M. tuberculosis*, and the analysis of mycobacterial proteins. We are grateful to Bandar Alrashid for the cloning of *cwsA* in pUAB400, Oliver Sampson for the optimization of MurJ~icd~ expression, and Angélique DeVisch for assistance with the FhaA binding experiments. The project was supported by the UK Biotechnology and Biological Sciences Research Council grants BB/H008586/1 and BB/P001513/1 (to G.V.M.), BB/P001289/1 (to W.V.), and Future Leaders Fellowship BB/N011945/1 (to P.J.M.); the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INBS-05 grant (to M.C.-G.); and the High Committee of Educational Development in Iraq (to B.K.).
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[^1]: Lead Contact

[^2]: CoA, coenzyme A. See also [Table S1](#mmc2){ref-type="supplementary-material"} and [Figure S1](#mmc1){ref-type="supplementary-material"}.

[^3]: Phosphorylated residues are shown in bold font.

[^4]: AG, advantageous for growth.
